Australia is manufacturing MDMA and psilocybin for therapeutic use, with companies like Breathe Life Sciences producing these drugs for patients with PTSD and treatment-resistant depression. While early results are promising, experts urge caution due to costs and potential side effects.
Australia is pioneering psychedelic medicine, with licensed facilities manufacturing MDMA for PTSD and psilocybin for depression. Patients like Jess Yugovich report life-changing therapeutic benefits, though experts caution about costs and suitability, emphasizing the distinction between regulated medical use and illicit street drugs.
President Donald Trump signed an executive order on Saturday aimed at accelerating psychedelics research, directing agencies to expand clinical trials and Right to Try access for psilocybin, MDMA and ibogaine. The order leaves drug scheduling unchanged and comes amid stalled cannabis rescheduling efforts, raising questions about whether psychedelics will face similar federal delays. Psychedelic stocks rallied significantly following the announcement, with AtaiBeckley jumping roughly 25%.
